Specifically, luminal A/B breast cancers are characterized as hormone receptor positive (high expression of ER and/or PR); HER2+ breast cancers are characterized by amplification of HER2 (and can be ER+ and/or PR+); and triple negative breast cancers (TNBCs) are characterized as hormone receptor negative and HER2 negative (ER−/PR−/HER2−) (Onitilo et al., 2009). Here, NR4A1 is linked to triple-negative breast carcinoma.